Synergized photothermal therapy and magnetic field induced hyperthermia via bismuthene for lung cancer combinatorial treatment

Thanks to its intrinsic properties, two-dimensional (2D) bismuth (bismuthene) can serve as a multimodal nanotherapeutic agent for lung cancer acting through multiple mechanisms, including photothermal therapy (PTT), magnetic field-induced hyperthermia (MH), immunogenic cell death (ICD), and ferropto...

Full description

Saved in:
Bibliographic Details
Published in:Materials today bio 2023-12, Vol.23, p.100825-100825, Article 100825
Main Authors: Yilmazer, Açelya, Eroglu, Zafer, Gurcan, Cansu, Gazzi, Arianna, Ekim, Okan, Sundu, Buse, Gokce, Cemile, Ceylan, Ahmet, Giro, Linda, Unal, Mehmet Altay, Arı, Fikret, Ekicibil, Ahmet, Ozgenç Çinar, Ozge, Ozturk, Berfin Ilayda, Besbinar, Omur, Ensoy, Mine, Cansaran-Duman, Demet, Delogu, Lucia Gemma, Metin, Onder
Format: Article
Language:English
Subjects:
Bismuthene
Cancer therapy
Full Length
Magnetic field induced hyperthermia
Photothermal therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thanks to its intrinsic properties, two-dimensional (2D) bismuth (bismuthene) can serve as a multimodal nanotherapeutic agent for lung cancer acting through multiple mechanisms, including photothermal therapy (PTT), magnetic field-induced hyperthermia (MH), immunogenic cell death (ICD), and ferroptosis. To investigate this possibility, we synthesized bismuthene from the exfoliation of 3D layered bismuth, prepared through a facile method that we developed involving surfactant-assisted chemical reduction, with a specific focus on improving its magnetic properties. The bismuthene nanosheets showed high in vitro and in vivo anti-cancer activity after simultaneous light and magnetic field exposure in lung adenocarcinoma cells. Only when light and magnetic field are applied together, we can achieve the highest anti-cancer activity compared to the single treatment groups. We have further shown that ICD-dependent mechanisms were involved during this combinatorial treatment strategy. Beyond ICD, bismuthene-based PTT and MH also resulted in an increase in ferroptosis mechanisms both in vitro and in vivo, in addition to apoptotic pathways. Finally, hemolysis in human whole blood and a wide variety of assays in human peripheral blood mononuclear cells indicated that the bismuthene nanosheets were biocompatible and did not alter immune function. These results showed that bismuthene has the potential to serve as a biocompatible platform that can arm multiple therapeutic approaches against lung cancer. In recent years, extensive research has been focused on exploring the capacity of two-dimensional (2D) materials in photothermal (PTT) or photodynamic therapy (PDT) of cancer. Other studies aimed to combine them with immunotherapies by inducing immunogenic cell death (ICG) following PDT/PTT induced apoptosis. More recently, ferroptosis, which is a type of cell death mechanism, has received much interest, especially in cancer cells resistant to apoptotic therapies. For this reason, ferroptosis therapy has been explored as an effective strategy in cancer nanotherapeutic. Combining all these therapeutic approaches in a single nanoplatform can be a wise strategy to fight with this disease; however, it has never been achieved until now, to the best of our knowledge. Our results showed that bismuthene has the potential to serve as a biocompatible platform that can arm multiple therapeutic approaches against lung cancer. We think that the results obtained in this study pave the w
ISSN:2590-0064
2590-0064
DOI:10.1016/j.mtbio.2023.100825